"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 5 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 3 | 5 |
| 2011 | 2 | 2 | 4 |
| 2012 | 3 | 0 | 3 |
| 2013 | 4 | 2 | 6 |
| 2014 | 2 | 5 | 7 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 1 | 4 |
| 2018 | 3 | 4 | 7 |
| 2019 | 2 | 4 | 6 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 6 | 8 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 2 | 3 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
Simultaneous Presentation of Cutaneous Waldenstr?m Macroglobulinemia and Acalabrutinib-Related Toxicity. Am J Dermatopathol. 2025 Oct 01; 47(10):786-789.
-
Calcium-Sensing Receptor as a Novel Target for the Treatment of Idiopathic Pulmonary Fibrosis. Biomolecules. 2025 04 01; 15(4).
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024 Dec; 13(24):e70226.
-
GVHD targets organoid-forming bile duct stem cells in a TGF-?-dependent manner. Blood. 2024 08 22; 144(8):904-913.
-
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024 Jul 22; 52(13):7740-7760.
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
-
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 12 01; 83(23):3956-3973.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 06 01; 22(6):717-725.
-
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.